Challenges
Malaria remains one of the world’s most life-threatening parasitic infectious diseases, with concentrated prevalence in tropical and subtropical regions and steadily rising imported case risks amid growing cross-border travel. For hospital outpatient and emergency departments, border quarantine authorities, grassroots clinics and frontline public health agencies, conventional malaria diagnostic approaches have four core unmet needs:
Limited accuracy and subtyping capacity of conventional testing
Traditional gold-standard microscopy relies heavily on experienced technicians, with low sensitivity for low-parasitemia infections that often lead to missed diagnoses. Rapid diagnostic tests (RDTs) only offer limited differentiation between Plasmodium falciparum and non-falciparum strains, and cannot accurately identify easily misdiagnosed species such as Plasmodium knowlesi or relapsing Plasmodium vivax. This lack of precise subtyping leads to inappropriate antimalarial therapy, unaddressed relapse risks, and delayed recognition of life-threatening severe falciparum malaria.
Delayed centralized diagnosis misses the narrow treatment window for severe malaria
Severe P. falciparum malaria can progress to organ failure and death within hours, requiring prompt targeted antimalarial intervention. Conventional nucleic acid testing relies on centralized molecular laboratories, with lengthy sample transport and batch processing workflows that delay results by hours to days. This lag directly worsens patient prognosis and slows on-site quarantine clearance at ports of entry.
High operational barriers limit access in endemic and frontline settings
Standard PCR-based malaria testing requires standardized molecular laboratories and certified technical personnel. These resources are largely unavailable in remote malaria-endemic regions, grassroots medical facilities, border checkpoints and field outbreak sites, leaving vast gaps in access to reliable, high-sensitivity malaria testing.
Inflexible throughput and cold chain reliance restrict grassroots deployment
Daily sample volumes in primary care settings are typically low, leaving high-throughput PCR instruments idle and cost-inefficient, while sudden outbreak surges demand rapid throughput expansion. Additionally, traditional reagents rely strictly on cold chain storage and transportation, creating further barriers to large-scale public health deployment in remote and tropical regions.
Core Benefits
The 4 Malaria Pathogen Nucleic Acid Detection Kit, paired with the Flex-Disc fully automated nucleic acid analysis platform, directly addresses the above outpatient, primary care and public health pain points:
One-stop 4-plex profiling for accurate Plasmodium identification and subtyping
A single run covers 4 targets: pan-Plasmodium (genus-level screening), P. falciparum, P. vivax and P. knowlesi. It delivers both initial infection confirmation and precise species differentiation, clearly identifying high-lethality falciparum malaria, relapsing vivax malaria and easily misdiagnosed knowlesi malaria. This enables clinicians to select targeted antimalarial regimens accurately, reduce inappropriate medication, and lower risks of severe disease and recurrence.
Results in around 40 minutes to seize the severe malaria treatment and quarantine window
Total testing time is around 40 minutes, with only 1 minute of hands-on sample loading — far faster than centralized laboratory PCR workflows. Rapid species-level results enable clinicians to initiate targeted antimalarial therapy promptly, reducing mortality from severe malaria. It also supports on-site rapid quarantine at ports of entry to speed up entry screening and block imported case transmission risks.
Low-barrier POCT deployment to expand testing accessibility
Powered by the fully automated closed Flex-Disc platform, the assay requires no standardized molecular laboratory or specialized technical staff, and can be operated by frontline medical workers after brief training. It can be deployed directly in infectious disease outpatient departments, grassroots clinics, border quarantine stations and endemic field sites, with on-demand testing for samples as they arrive. This significantly shortens diagnostic turnaround time and extends access to high-quality molecular malaria testing to underserved settings.
Modular scalable throughput to adapt to diverse scenario needs
Each independent Flex-Disc testing module processes one sample at a time, with a single control terminal supporting wireless connection to up to 8 modules simultaneously. Facilities can scale the number of modules according to actual sample volume: a single module meets routine primary care and outpatient demand, while multi-module parallel operation handles outbreak surges and mass field screening, balancing operational cost and testing capacity.
Core Product Advantages
Guideline-aligned 4-plex panel for dual clinical and public health use
The panel covers pan-Plasmodium and three clinically critical malaria species (P. falciparum, P. vivax, P. knowlesi), fully aligned with WHO malaria testing guidelines. It is suitable for severe malaria diagnosis, travel medicine screening, entry-exit port quarantine and endemic outbreak surveillance, meeting the needs of both hospital outpatient departments and public health agencies.
Fully automated closed sample-to-result workflow
Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true load-and-go detection.
Modular scalable throughput design for flexible deployment
Compatible with the Flex-Disc (Model: CH-0104) Fully Automated Nucleic Acid Analyzer, each testing module processes 1 sample per run with full results available in around 40 minutes. One main control terminal can connect wirelessly to up to 8 testing modules, supporting random access and parallel testing to flexibly match sample volumes from small grassroots clinics to hospital outpatient and public health screening sites.

Lyophilized reagents for room-temperature storage and transport
With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance. This greatly reduces storage and logistics costs for tropical endemic regions, remote grassroots sites and field testing scenarios.
Zero cross-contamination closed cartridge system
Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces on-site quality control requirements, and ensures stable, reliable results even in non-laboratory field settings.
CE-compliant with validated whole blood sample compatibility
The assay is fully validated for human venous whole blood samples with EDTA anticoagulation. All 4 targets are CE-marked, meeting regulatory requirements for clinical diagnosis, public health surveillance and border quarantine across global primary care and outpatient markets.